Nucleic acid fragment from the chromosome x region involved in the fragile x syndrome, nucleotide probe and method for the diagnosis of mental retardation with fragile x
CA 2104110 C · Owner: Institut National De La Sante Et De La Recherche Medicale (Inserm) · Inventors: Mandel, Jean-Louis; Heitz, Dominique; Vincent, Anne
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Nucleic acid fragment containing mutations associated with the fragile X syndrome or other DNA anomalies resulting from these mutations such as methylations of CpG sites. Nucleotide probe for detecting these mutations and DNA anomalies associated with mental retardation with fragile X and method for diagnosing mental retardation with fragile X.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed February 13, 1992 and granted December 9, 2003. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended February 13, 2012.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by February 13, 2014.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.